CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells

Melissa M Gresle, Margaret A Jordan, Jim Stankovich, Tim Spelman, Laura J Johnson, Louise Laverick, Alison Hamlett, Letitia D Smith, Vilija G Jokubaitis, Josephine Baker, Jodi Haartsen, Bruce Taylor, Jac Charlesworth, Melanie Bahlo, Terence P Speed, Matthew A Brown, Judith Field, Alan G Baxter, Helmut Butzkueven

2020-07-01

At least 200 single-nucleotide polymorphisms (SNPs) are associated with multiple sclerosis (MS) risk. A key function that could me..

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

Ai-Lan Nguyen, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Tomas Kalincik, Anneke van der Walt, Murat Terzi, Raed Alroughani, Pierre Duquette, Marc Girard, Alexandre Prat, Cavit Boz, Patrizia Sola, Diana Ferrara, Alessandra Lugaresi, Jeannette Lechner-Scott, Michael Barnett, Francois Grand'Maison, Pierre Grammond, Cristina Ramo-Tello

2019-02-01

BACKGROUND: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be ..

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Jordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, Raymond Hupperts, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Cristina Ramo-Tello, Maria Trojan, Mark Slee, Vahid Shaygannejad, Cavit Boz, Jeanette Lechner-Scott, Vincent Van Pesch, Eugenio Pucci

2018-11-01

IMPORTANCE: The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) ..

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

Tim Spelman, Claire Meyniel, Juan Ignacio Rojas, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'Maison, Cavit Boz, Raed Alroughani, Eva Havrdova, Dana Horakova, Gerardo Iuliano, Pierre Duquette, Murat Terzi, Pierre Grammond, Raymond Hupperts, Jeannette Lechner-Scott, Celia Oreja-Guevara, Eugenio Pucci, Freek Verheul, Marcela Fiol

2017-09-01

BACKGROUND: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk ..

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Tomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Marc Girard, Alexandre Prat, Pierre Duquette, Pierre Grammond, Patrizia Sola, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Cavit Boz, Raed Alroughani

2017-09-01

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response var..

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Bernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, Eva Havrdova, Tomas Kalincik

2017-06-01

BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with im..

Data quality evaluation for observational multiple sclerosis registries

Tomas Kalincik, Jens Kuhle, Eugenio Pucci, Juan Ignacio Rojas, Magda Tsolaki, Carmen-Adella Sirbu, Mark Slee, Helmut Butzkueven

2017-04-01

OBJECTIVE: Objective and reproducible evaluation of data quality is of paramount importance for studies of 'real-world' observatio..

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard

2017-04-01

BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relap..

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Nathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, Jeannette Lechner-Scott, Mark Slee, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Pierre Grammond, Raymond Hupperts, Francois Grand'Maison, Patrizia Sola, Eugenio Pucci, Roberto Bergamaschi, Celia Oreja-Guevara, Vincent Van Pesch

2017-03-01

OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple scle..

Contribution of different relapse phenotypes to disability in multiple sclerosis

Tamasine Stewart, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Vahid Shaygannejad, Raymond Hupperts, Raed Alroughani, Celia Oreja-Guevara, Eugenio Pucci, Cavit Boz, Jeannette Lechner-Scott

2017-02-01

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Raed Alroughani, Patrizia Sola, Cavit Boz, Eugenio Pucci, Jeanette Lechner-Scott

2016-09-01

Pregnancy protects against long-term disability accrual in relapsing-remitting MS

VG Jokubaitis, T Kalincik, J Lorscheider, T Spelman, D Horakova, P Duquette, M Girard, A Prat, G Izquierdo, P Grammond, E Pucci, F Grand'Maison, F Granella, P Sola, R Bergamaschi, G Iuliano, D Spitaleri, S Hodgkinson, J Olascoaga, F Verheul

2016-09-01

The antiepileptic medications carbamazepine and phenytoin inhibit native sodium currents in murine osteoblasts

Sandra J Petty, Carol J Milligan, Marian Todaro, Kay L Richards, Pamuditha K Kularathna, Charles N Pagel, Chris R French, Elisa L Hill-Yardin, Terence J O'Brien, John D Wark, Eleanor J Mackie, Steven Petrou

2016-09-01

OBJECTIVE: Fracture risk is a serious comorbidity in epilepsy and may relate to the use of antiepileptic drugs (AEDs). Many AEDs i..

Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis

Vilija G Jokubaitis, Tim Spelman, Tomas Kalincik, Johannes Lorscheider, Eva Havrdova, Dana Horakova, Pierre Duquette, Marc Girard, Alexandre Prat, Guillermo Izquierdo, Pierre Grammond, Vincent Van Pesch, Eugenio Pucci, Francois Grand'Maison, Raymond Hupperts, Franco Granella, Patrizia Sola, Roberto Bergamaschi, Gerardo Iuliano, Daniele Spitaleri

2016-07-01

OBJECTIVE: To identify predictors of 10-year Expanded Disability Status Scale (EDSS) change after treatment initiation in patients..

Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS

Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Shibeshih Belachew, Robert Hyde, Freek Verheul, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Pierre Grammond, Pierre Duquette, Alexandre Prat, Gerardo Iuliano, Murat Terzi, Guillermo Izquierdo, Raymond MM Hupperts, Cavit Boz

2016-04-01

BACKGROUND: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis..

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, Francois Grand'Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolanos, Marcela Fiol

2016-04-01

OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatmen..

How is the sustainability of chronic disease health programmes empirically measured in hospital and related healthcare services?a scoping review

Linda Francis, David Dunt, Dominique A Cadilhac

2016-01-01

OBJECTIVES: Programmes to address chronic disease are a focus of governments worldwide. Despite growth in 'implementation science'..

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Tim Spelman, Orla Gray, Robyn Lucas, Helmut Butzkueven

2015-12-01

This report describes a novel Stata-based application of trigonometric regression modelling to 55 years of multiple sclerosis rela..

Defining reliable disability outcomes in multiple sclerosis

Tomas Kalincik, Gary Cutter, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Celia Oreja-Guevara, Cavit Boz, Eugenio Pucci, Roberto Bergamaschi, Jeannette Lechner-Scott

2015-11-01

Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. Th..

Mind the gap: Multiple events and lengthy delays before presentation with a "first seizure"

Anna L Firkin, David JT Marco, Sibel Saya, Mark R Newton, Terence J O'Brien, Samuel F Berkovic, Anne M McIntosh

2015-10-01

OBJECTIVE: Up to half of patients assessed for suspected new-onset epileptic seizures report previous undiagnosed events. This sug..

SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia

M Udawela, TT Money, J Neo, MS Seo, E Scarr, B Dean, IP Everall

2015-08-04

Selenium binding protein 1 (SELENBP1) messenger RNA (mRNA) has previously been shown to be upregulated in the brain and blood from..

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Pierre Grammond, Alessandra Lugaresi, Celia Oreja-Guevara, Roberto Bergamaschi, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Vincent Van Pesch, Cavit Boz, Gerardo Iuliano, Ricardo Fernandez-Bolanos, Shlomo Flechter, Daniele Spitaleri, Edgardo Cristiano, Freek Verheul

2015-08-01

BACKGROUND: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been in..

Galanin is an Autocrine Myelin and Oligodendrocyte Trophic Signal Induced by Leukemia Inhibitory Factor

Melissa M Gresle, Helmut Butzkueven, Victoria M Perreau, Anna Jonas, Junhua Xiao, Stefan Thiem, Fiona E Holmes, William Doherty, Pik-Ying Soo, Michele D Binder, Rainer Akkermann, Vilija G Jokubaitis, Holly S Cate, Mark P Marriott, Andrew L Gundlach, David Wynick, Trevor J Kilpatrick

2015-06-01

In order to further investigate the molecular mechanisms that regulate oligodendrocyte (OC) survival, we utilized microarrays to c..

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella

2015-04-01

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicia..

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson

2015-03-01

OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians..

Single live cell TGF-beta signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-beta-Smad3 activity

Rodney B Luwor, Dulani Hakmana, Josephine Iaria, Thao V Nheu, Richard J Simpson, Hong-Jian Zhu

2015-02-22

BACKGROUND: Metastasis is a process where only a small subset of cells is capable of successfully migrating to and propagating at ..

Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent

Tim Spelman, Orla Gray, Maria Trojano, Thor Petersen, Guillermo Izquierdo, Alessandra Lugaresi, Raymond Hupperts, Roberto Bergamaschi, Pierre Duquette, Pierre Grammond, Giorgio Giuliani, Cavit Boz, Freek Verheul, Celia Oreja-Guevara, Michael Barnett, Francois Grand'Maison, Maria Edite Rio, Jeannette Lechner-Scott, Vincent Van Pesch, Ricardo Fernandez Bolanos

2014-12-01

OBJECTIVE: Previous studies assessing seasonal variation of relapse onset in multiple sclerosis have had conflicting results. Smal..

Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation

Anna Jonas, Stefan Thiem, Tanja Kuhlmann, Raimund Wagener, Attila Aszodi, Cameron Nowell, Mann Hagemeier, Louise Laverick, Victoria Perreau, Vilija Jokubaitis, Ben Emery, Trevor Kilpatrick, Helmut Butzkueven, Melissa Gresle

2014-11-01

In patients with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE), inflammatory axonal injury..

Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients

MM Gresle, Y Liu, LF Dagley, J Haartsen, F Pearson, AW Purcell, L Laverick, A Petzold, RM Lucas, A Van der Walt, H Prime, DR Morris, BV Taylor, G Shaw, H Butzkueven

2014-11-01

OBJECTIVES: We evaluated whether the measurement of serum phosphorylated neurofilament heavy chain (pNF-H) titre is likely to be a..

Risk of relapse phenotype recurrence in multiple sclerosis

Tomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, Maria Trojano, Pierre Duquette, Guillermo Izquierdo, Marc Girard, Alessandra Lugaresi, Pierre Grammond, Francois Grand'Maison, Celia Oreja-Guevara, Cavit Boz, Raymond Hupperts, Thor Petersen, Giorgio Giuliani, Gerardo Iuliano, Jeannette Lechner-Scott, Michael Barnett, Roberto Bergamaschi, Vincent Van Pesch

2014-10-01

OBJECTIVES: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of de..

Weight and fat distribution in patients taking valproate: A valproate-discordant gender-matched twin and sibling pair study

Sandra J Petty, Susan Kantor, Kate M Lawrence, Samuel F Berkovic, Marnie Collins, Keith D Hill, Joanna Makovey, Philip N Sambrook, Terence J O'Brien, John D Wark

2014-10-01

OBJECTIVES: Chronic treatment with valproate (VPA) is commonly associated with weight gain, which potentially has important health..

Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity

Nelson Ung, Tracy L Putoczki, Stanley S Stylli, Irvin Ng, John M Mariadason, Timothy A Chan, Hong-Jian Zhu, Rodney B Luwor

2014-05-01

Several agents targeting the epidermal growth factor receptor (EGFR) have been FDA-approved to treat cancer patients with varying ..

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Tomas Kalincik, Vino Vivek, Vilija Jokubaitis, Jeannette Lechner-Scott, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Francois Grand'Maison, Raymond Hupperts, Celia Oreja-Guevara, Roberto Bergamaschi, Gerardo Iuliano, Raed Alroughani, Vincent Van Pesch, Maria Pia Amato, Mark Slee, Freek Verheul, Ricardo Fernandez-Bolanos, Marcela Fiol, Daniele La Spitaleri

2013-12-01

The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship betw..

Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months

Atte Meretoja, Louise Weir, Melissa Ugalde, Nawaf Yassi, Bernard Yan, Peter Hand, Melinda Truesdale, Stephen M Davis, Bruce CV Campbell

2013-09-17

OBJECTIVE: To test the transferability of the Helsinki stroke thrombolysis model that achieved a median 20-minute door-to-needle t..

Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location

Minmin Ma, Atte Meretoja, Leonid Churilov, Gagan J Sharma, Soren Christensen, Xinfeng Liu, Louise Weir, Stephen M Davis, Bernard Yan

2013-09-15

BACKGROUND: Warfarin use increases mortality in patients with intracerebral hemorrhage (ICH). Larger hematoma volume and infratent..

The role of Stat3 in glioblastoma multiforme

Rodney B Luwor, Stanley S Stylli, Andrew H Kaye

2013-07-01

Glioblastoma multiforme (GBM) is the most common brain tumor and has the worst prognosis. Several signaling molecules have been cl..

Younger Siblings, C-Reactive Protein, and Risk of Age-Related Macular Degeneration

Amy C Cohn, Lucy Busija, Liubov D Robman, Peter N Dimitrov, Mary Varsamidis, Lyndell L Lim, Paul N Baird, Robyn H Guymer

2013-05-01

In this study, we examined the relationship between exposure to siblings and 1) the risk of age-related macular degeneration (AMD)..

Do Patients Who Take Part in Stroke Research Differ from Non-Participants? Implications for Generalizability of Results

Lucy Busija, Lingwei William Tao, Danny Liew, Louise Weir, Bernard Yan, Gabriel Silver, Stephen Davis, Peter J Hand

2013-01-01

BACKGROUND: Stroke is one of the most disabling neurological conditions. Clinical research is vital for expanding knowledge of tre..

A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor

Anneke Van der Walt, Simon Sung, Timothy Spelman, Mark Marriott, Scott Kolbe, Peter Mitchell, Andrew Evans, Helmut Butzkueven

2012-07-01

OBJECTIVE: To evaluate the safety and efficacy of botulinum toxin type A in disabling multiple sclerosis (MS)-related upper limb t..

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome

Claire Meyniel, Timothy Spelman, Vilija G Jokubaitis, Maria Trojano, Guillermo Izquierdo, Francois Grand'Maison, Celia Oreja-Guevara, Cavit Boz, Alessandra Lugaresi, Marc Girard, Pierre Grammond, Gerardo Iuliano, Marcela Fiol, Jose Antonio Cabrera-Gomez, Ricardo Fernandez-Bolanos, Giorgio Giuliani, Jeannette Lechner-Scott, Edgardo Cristiano, Joseph Herbert, Tatjana Petkovska-Boskova

2012-06-29

OBJECTIVES: We conducted a prospective study, MSBASIS, to assess factors leading to first treatment discontinuation in patients wi..

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

Stella Hughes, Timothy Spelman, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'Maison, Pierre Duquette, Marc Girard, Pierre Grammond, Celia Oreja-Guevara, Raymond Hupperts, Cavit Boz, Roberto Bergamaschi, Giorgio Giuliani, Maria Edite Rio, Jeannette Lechner-Scott, Vincent van Pesch, Gerardo Iuliano, Marcela Fiol, Freek Verheul

2012-03-01

BACKGROUND: The Expanded Disability Status Scale (EDSS) is widely used to rate multiple sclerosis (MS) disability, but lack of dis..